Shares of Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) traded at a new 52-week high today of $5.50. This new high was reached on below average trading volume as 1.5 million shares traded hands, while the average 30-day volume is approximately 3.4 million shares.
There is potential upside of 128.7% for shares of Rigel Pharmaceuticals Inc. based on a current price of $5.20 and an average consensus analyst price target of $11.88.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm’s lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken over all responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes Fostamatinib – ITP, Fostamatinib – AIHA, Fostamatinib – IgAN, BGB324 – Oral AXL Inhibitor, ATI-50001 & 50002 – JAK Inhibitors, DS-3032-MDM2 Inhibitor, THF-beta Inhibitors and AZD0449- Inhaled JAK Inhibitor.
In the past 52 weeks, Rigel Pharmaceuticals Inc. share prices are bracketed by a low of $1.23 and a high of $5.50 and is now at $5.20, 322% above that low price.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer